CareDx, Inc
NasdaqGM:CDNA Stok Raporu
CareDx Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6 CareDx şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler Toplam Hissedar Getirisi 2.3% Gelecekteki Temettü Verimi 0% Temettü Büyümesi n/a Bir sonraki temettü ödeme tarihi n/a Eski temettü tarihi n/a Hisse başına temettü n/a Ödeme oranı n/a
Son temettü ve geri alım güncellemeleri CareDx, Inc (NasdaqGM:CDNA) announces an Equity Buyback for $50 million worth of its shares. Dec 07
Tüm güncellemeleri göster
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26% Nov 05
Caredx, Inc Raises Revenue Guidance for the Full Year 2024 Nov 05
CareDx, Inc to Report Q3, 2024 Results on Nov 04, 2024 Oct 15
CareDx, Inc Appoints Jing Huang as Chief Data and Artificial Intelligence (AI) Officer Oct 09
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics Sep 29
CareDx, Inc Appoints Keith Kennedy as Chief Operating Officer Sep 12
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too Aug 01
CareDx, Inc Revises Earnings Guidance for the Full Year 2024 Aug 01
CareDx, Inc to Report Q2, 2024 Results on Jul 31, 2024 Jul 16
CareDx: Benefiting From Some Certainty Jul 15
CareDx, Inc Announces New Data to Be Presented At the 2024 American Transplant Congress May 31
Study Shows CareDx, Inc.’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies May 18
Price target increased by 11% to US$14.40 May 12
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 10
Executive Director exercised options to buy US$123k worth of stock. May 03 CareDx, Inc, Annual General Meeting, Jun 13, 2024
Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge Apr 27 CareDx, Inc Appoints John W. Hanna as Chief Executive Officer
CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors Mar 12
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too Mar 02
Full year 2023 earnings: EPS misses analyst expectations Mar 01
CareDx, Inc Provides Revenue Guidance for the Full Year of 2024 Feb 29 CareDx, Inc to Report Q4, 2023 Results on Feb 28, 2024
Jury Rules in Favor of Natera, Inc in Patent Infringement Lawsuit Against CareDx, Inc Jan 29 CareDx, Inc Provides Earnings Guidance for Fourth Quarter Ended December 31, 2023
Price target increased by 11% to US$11.80 Jan 04
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry Dec 27
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too Dec 27
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents Dec 12
CareDx, Inc to Report Q3, 2023 Results on Nov 08, 2023 Nov 03 CareDx, Inc Announces Resignation of Reginald Seeto as Chief Executive Officer
CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents Oct 05
CareDx, Inc Announces Executive Changes Sep 27 SEC Concludes Investigation as to CareDx and Does Not Intend to Recommend an Enforcement Action Sep 26
Price target decreased by 16% to US$10.80 Aug 15
Consensus EPS estimates fall by 14% Aug 15
Independent Director exercised options to buy US$173k worth of stock. Aug 14
New major risk - Revenue and earnings growth Aug 09
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 09
CareDx, Inc. Provides Revenue Guidance for the Full Year 2023 Aug 09
CareDx, Inc to Report Q2, 2023 Results on Aug 08, 2023 Aug 04
CareDx, Inc. Announces Medicare Coverage for HeartCare Aug 03
Price target increased by 26% to US$12.60 Jul 26
CareDx, Inc (NasdaqGM:CDNA) acquired MediGO, Inc. Jul 26
CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring Jul 12
New minor risk - Share price stability Jul 09
President notifies of intention to sell stock Jul 02
Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price Jun 29
Consensus revenue estimates fall by 13% May 17
Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA) May 16
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 11
CareDx, Inc to Report Q1, 2023 Results on May 10, 2023 May 09
Consensus EPS estimates fall by 10% Mar 06
Price target decreased by 22% to US$20.40 Mar 03
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Mar 01
CareDx, Inc. Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions At the 2023 Tandem Meetings Feb 17
Executive Director notifies of intention to sell stock Feb 13
Executive Director notifies of intention to sell stock Feb 09
Price target decreased by 7.6% to US$26.17 Feb 06
CareDx, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 10
President notifies of intention to sell stock Jan 09
Executive Officer notifies of intention to sell stock Dec 20 CareDx, Inc (NasdaqGM:CDNA) announces an Equity Buyback for $50 million worth of its shares. Dec 07
CareDx, Inc Announces the Results of A New Study Published in Transplantation Direct Dec 02
CareDx, Inc Announces Resignation of Ralph Snyderman as Director, Effective from December 31, 2022 Nov 24
Price target decreased to US$30.00 Nov 16
Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.23 loss in 3Q 2021) Nov 04
Caredx, Inc., Revises Revenue Guidance for the Full Year 2022 Nov 04
Independent Longitudinal Study Finds Caredx’S Allosure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients Nov 02
CareDx, Inc to Report Q3, 2022 Results on Nov 03, 2022 Oct 27
CareDx: Shaking Off First-Mover Disadvantage Oct 18
Caredx, Inc Announces Transplant Patients Experience Less Pain and Fewer Adverse Events with Caredx Non-Invasive Testing Solutions Sep 28 CareDx, Inc Announces Executive Changes
CareDx, Inc Announces Resignation of Sasha King as Chief Marketing Officer Sep 02
Executive Director notifies of intention to sell stock Aug 15
Independent Director recently sold US$63k worth of stock Aug 13
Consensus EPS estimates fall by 20% Aug 11
Price target decreased to US$45.67 Aug 08
CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers Aug 08
CareDx, Inc Revises Revenue Guidance for the Full Year 2022 Aug 06
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 05
CareDx Launches Personalized AlloHome Patient Monitoring Solution to Augment Pre- and Post-Transplant Care Aug 03
CareDx, Inc to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Caredx, Inc Jun 25 Saxena White P.A. Files New Securities Fraud Class Action Against CareDx, Inc
Natera Drops One of Their Two Patents Originally Asserted Against CareDx, Inc May 19
Independent Director recently sold US$119k worth of stock May 15
Consensus forecasts updated May 12
Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: CDNA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: CDNA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi CareDx Piyasaya Karşı Temettü Getirisi
CDNA temettü verimi piyasa ile karşılaştırıldığında nasıldır? Segment Temettü Verimi Şirket (CDNA) n/a Pazarın Alt %25'i (US) 1.3% Pazarın En İyi %25'i (US) 4.3% Sektör Ortalaması (Biotechs) 2.1% Analist tahmini (CDNA) (3 yıla kadar) 0%
Önemli Temettü: CDNA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CDNA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: CDNA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranı nı hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: CDNA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
